Skip to content
Generic

Pricing and reimbursement of drugs and medical devices in Hungary

Gulácsi L, Dávid T, Dózsa C ...see all

European Journal of Health Economics, vol. 3, issue 4 (2002) pp. 271-278

  • 18

    Readers

    Mendeley users who have this article in their library.
  • 15

    Citations

    Citations of this article.
  • N/A

    Views

    ScienceDirect users who have downloaded this article.
Sign in to save reference

Abstract

Similarly to other countries of Central and Eastern Europe, Hungary has witnessed massive diffusion of healthcare technology such as drugs and medical devices since 1990. While substantial new pharmaceuticals, medical devices, and procedures have been liberalized, there has been no proper evaluation or training in their use. Healthcare providers have come to find themselves as entrepreneurs in private practice, while patients are acquiring an increasing awareness as customers of healthcare,demanding services in return for their taxes and contributions. This has led to extremely irrational patterns of investment in technology, with most an obvious waste of resources, while leaving basic needs unmet. Both the National Health Insurance Fund and the Ministry of Finance believe that the current pharmaceutical and medical device bill is too high. However, introducing a more transparent and flexible pricing and reimbursement framework may enable a more efficient allocation of the limited resources to be achieved.

Author-supplied keywords

  • Healthcare expenditure
  • Healthcare financing
  • Healthcare privatization
  • Hungary
  • Pharmaceutical pricing and reimbursement

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Laszlo Gulácsi

  • T. Dávid

  • Cs Dózsa

Cite this document

Choose a citation style from the tabs below